Introduction {#s1}
============

Osteoporosis may result from imbalanced bone metabolism leading to a systemic deterioration in bone mass and bone microstructure, characterized by skeletal fragility and an increased risk of bone fracture ([@B1]; [@B129]). Almost one in three women and one in five men would experience one bone fracture in their life after 50 years of age, resulting from osteoporosis ([@B139]). Furthermore, the risk of additional fractures will rise exponentially with each incidence of fracture ([@B98]). Osteoporosis is, therefore, a debilitating disease for sufferers, leading to reduced quality of life, and places a large economic burden on society ([@B20]). Thus, medical intervention is imperative to provide adequate care for patients and improve societal health. Moreover, it is necessary to continue research leading to the development of a medical treatment that may effectively treat and potentially prevent osteoporosis ([@B157]).

Currently, there are numerous pharmacological products used for the treatment of osteoporosis in the clinic ([@B125]). Hormone replacement therapy (HRT) and bisphosphonates are the primary therapeutic strategies for bone loss diseases including osteoporosis ([@B40]). Long-term HRT may significantly increase the risk of endometrial and mammary cancer, and coronary heart disease and other cardiovascular diseases ([@B21]; [@B22]). While bisphosphonates may lead to osteonecrosis of the long bones and jaws ([@B140]; [@B99]). These adverse side-effects limit the clinical use of HRT and bisphosphonates. Therefore, alternative therapeutic agents are required to develop medicines for the treatment of osteoporosis that are less likely to have adverse side-effects.

Traditional Chinese medicine (TCM) has become increasingly popular due to its effectiveness in treating diseases, with fewer side-effects. Natural Chinese medicine has been widely and effectively used to treat a variety of orthopaedic diseases, including bone fractures, rheumatism, and osteoporosis ([@B112]; [@B40]; [@B142]). Some TCMs are the most classical and bone-specific of drugs when applied to the treatment of bone loss and bone fracture diseases, with the effects on the growth and development of skeleton tissue ([@B136]; [@B155]). Recent scientific reports suggest that these natural Chinese medicine therapies appear to have both the anabolic and anticatabolic effects for the treatment of osteoporosis by promoting bone formation and attenuating imbalanced bone resorption, leading to improved bone mineral density and biomechanical properties, and reduced bone microstructural degradation ([**Figure 1**](#f1){ref-type="fig"}) ([@B40]; [@B157]; [@B142]). Further, *in vitro* findings indicate that these natural medicines may enhance the proliferation and survival of osteoblasts, and they could induce the differentiation of osteoblast cells from bone mesenchymal stem cells (MSCs). While the bone catabolic effects of osteoclastogenesis and bone resorption were effectively inhibited ([**Figure 2**](#f2){ref-type="fig"}).

![The therapeutic potential of natural Chinese medicine for the treatment of osteoporosis. The bone quality will be seriously impaired facing the challenges of estrogen or androgen deficiency, excessive hormone drugs, and weightlessness. While some of the natural Chinese medicines could act as potential candidates to improve the skeleton formation and inhibit bone loss. (OVX, ovariectomization; GC, Glucocorticoid; HLS, Hind Limb Suspension).](fphar-10-01344-g001){#f1}

![Natural Chinese medicine could promote the proliferation (Pr) and differentiation of osteoblasts and bone mesenchymal stem cells, enhance the osteogenesis ability, and inhibit the apoptosis (Ap) of osteoblasts induced by oxidative stress. While the osteoclastogenesis and bone-resorption function of osteoclasts are inhibited by their beneficial effects.](fphar-10-01344-g002){#f2}

Therefore, we selected the natural Chinese medicines, which are the classical bone-specific drugs for the bone loss and fracture diseases in clinic, including *Gynochthodes officinalis* (F.C.How) Razafim. & B.Bremer (syn. *Morinda officinalis* F.C.How), *Curculigo orchioides* Gaertn., *Psoralea corylifolia (L.) Medik, Eucommia ulmoides* Oliv., *Dipsacus inermis* Wall. (syn. *Dipsacus asperoides C.Y.Cheng & T.M.Ai*), *Cibotium barometz* (L.) J. Sm., Velvet Antler, and so on. Then, according to the literature search of PubMed, each natural Chinese medicine was searched with the keywords of bone, osteoporosis, bone loss, osteolysis, bone formation, skeleton, osteogenesis, osteoclastogenesis, antibone resorption, bone resorption, bone absorption, therapeutic, osteoblasts, osteoclasts, bone mesenchymal stem cell, differentiation, apoptosis, formula, and combination, accompanied with the Boolean connectors of "AND", "OR", and "NOT". After careful reading, the medicines with both anabolic and anticatabolic effects were included and reviewed. Medicines without osteoporosis-related research, or without both anabolic and anticatabolic benefits, or with flaws in experimental design were excluded. Despite the massive amount of experimental data regarding antiosteoporotic effects by the natural Chinese medicines from the *in vivo* and *in vitro* studies, high-quality clinical trials are lacking. Additionally, this review highlights and evaluates the scientific evidence for the potential use of natural Chinese medicines in the treatment of osteoporosis with both therapeutic anabolic and anticatabolic benefits, and their potential mechanisms of action.

Natural Chinese Medicines {#s2}
=========================

*Gynochthodes officinalis* (F.C.How) Razafim. & B.Bremer (syn. *Morinda officinalis* F.C.How) {#s2_1}
---------------------------------------------------------------------------------------------

*Gynochthodes officinalis* (F.C.How) Razafim. & B.Bremer (syn. *Morinda officinalis* F.C.How) (MO, "Ba-Ji-Tian") is a famous natural herb in Chinese medicine, containing many bioactive components including oligosaccharides, iridoid glycosides, and bajijiasu ([@B7]; [@B178]; [@B66]). Recent studies have found that it could enhance sexual and reproductive function; and may ameliorate Alzheimer's disease *via* the microbiota-gut-brain axis, providing benefits including improved memory and learning abilities ([@B178]; [@B8]). Additionally, the components of polysaccharides, monotropein and bajijiasu could act as potential agents to treat osteoporosis.

The protective effects of MO root extract on ovariectomy-induced bone loss have been reported ([@B71]). Findings indicate that MO root extract could enhance the bone mineral content (BMC) and bone mineral density (BMD) of the tibia in ovariectomized (OVX) rats ([@B71]). The levels of serum phosphorus (P), calcium(Ca), and osteoprotegerin (OPG) increased, and the levels of serum deoxypyridinoline crosslinks to creatinine ratio (DPD/Cr), tartrate-resistant acid phosphatase (TRAcP), adrenocorticotropin (ACTH), and corticosterone decreased, but did not reverse the levels of serum alkaline phosphatase (ALP), tumor necrosis factor-α (TNF-α), or interleukin-6 (IL-6) ([@B71]). Correspondingly, MO capsules attenuated the ovariectomy-induced loss of bone mass by enhancing bone strength, and reducing further deterioration of the trabecular microarchitecture of the femurs in rats, which was associated with increased serum osteocalcin (OC) levels ([@B77]). Polysaccharides are the extract isolated from MO that could significantly elevate whole femoral BMD as compared with the osteoporosis group. The mineral levels of Ca, P, Mg, Zn, Mn, Cu, and Fe in the femur were enhanced dose-dependently ([@B212]). Monotropein is a natural compound extracted from MO that appears to exhibit antiosteoporotic effects by increasing BMC, BMD, bone volume fraction (BVF), and attenuating trabecular microstructural degradation in OVX rodents ([@B212]; [@B207]). In vivo findings from a disuse-model of osteoporosis indicate that MO dried-root extracts exhibit both bone formation activity and appear to suppress bone resorption. Mornidae Radix (MR), the dried-root of MO, was found to inhibit the osteoporosis-induced decrease of hind limb thickness, tibia failure load, BMD, and tibia Ca and P levels ([@B131]). Histomorphometry results indicated that it could remarkably protect tibiae's bone parameters, including volume, length, and cortical and trabecular thickness. Furthermore, both preventive and therapeutic studies indicated that the effects of MR appear to be favourable for both the prevention and treatment of osteoporosis ([@B131]).

Consistently, *in vitro* studies have found that MO and its bioactive components appear to provide potentially therapeutic treatment for osteoporosis, and that the molecular mechanisms appear to act *via* receptor activator of nuclear factor kappa-B ligand (NF-κB, or RANKL) signalling pathways. For example, rubiadin-1-methyl ether (RBM, a natural anthraquinone compound isolated from the root of MO) may effectively inhibit osteoclastic bone resorption by blocking the NF-κB pathway ([@B42]). Bajijiasu was found to inhibit osteoclast formation and bone resorption *via* the mediation of RANKL signalling pathways ([@B45]). Expression of RANKL-induced marker genes, including cathepsin *K (CTSK)*, nuclear factor of activated T cells cytoplasmic 1 (NFATc1), TRAcP, vacuolar-type H+-ATPase V0 subunit D2 (V-ATPase d2), and matrix metalloproteinase-2 (MMP-2) was inhibited by Bajijiasu ([@B45]). Further *in vitro* studies of anthraquinones isolated from MO have identified these molecules as potential inhibitors of osteoclastic bone resorption and enhancers of osteoblastic bone-forming activity ([@B177]; [@B2]). MO-anthraquinones have demonstrated the ability to decrease the formation of bone resorption pits, the number of multinucleated osteoclasts, and the activity of tartrate resistant acid phosphates (TRAP) in an osteoblast-bone marrow coculture system, in addition to expediting the apoptosis of osteoclasts ([@B2]). MO-anthraquinones also appear to promote osteoblastic bone-forming activity by increasing osteoblast proliferation and ALP activity ([@B177]). Investigation of the polysaccharides extracted from MO revealed that osteogenic inulins of MO promote the proliferation, differentiation, and mineralization of osteoblast cells, as confirmed by the up-regulation of marker genes, including runt-related transcription factor 2, osterix, osteocalcin, bone sialoprotein, and OPG ([@B52]).

Taken together, these findings suggest that MO and its bioactive components might provide an important therapeutic role for the treatment and prevention of osteoporosis. MO appears to provide potentially effective treatment for osteoporosis by the attenuation of bone loss and trabecular microstructural degradation, the enhancement of bone mineral density and bone mass, the promotion of osteoblastic bone-forming activity, and the inhibition of osteoclastic bone resorption by direct effects on osteoclasts and effects mediated *via* known signalling pathways. In the *in vitro* research, the effective concentration of Bajijiasu compound was found to be 0.8 mM ([@B45]), which may be higher than compounds in other *in vitro* experiments, and the clinical usage may be increased to get better curative effects, therefore, a careful caution of the safety should be observed. Further research is needed to develop the therapeutic potential of this natural medicine.

*Curculigo orchioides* Gaertn {#s2_2}
-----------------------------

There are more than 20 species of *Curculigo* plants in the world. They are native to the tropical and subtropical regions of Asia, Africa, South America, and Oceania ([@B116]). *Curculigo orchioides* Gaertn (CO, "Xian Mao"), one of curculigo species, is used to relieve the symptoms of limb weakness, lumbar and knee joint arthritis, and diarrhea in Chinese medicine ([@B145]). Recent studies have found that CO also appears to have antioxidant properties and anticancer potential, and may be used as an antiosteoporotic herb ([@B4]; [@B130]; [@B43]).

CO is used in Chinese medicine for the treatment of postmenopausal osteoporosis and the antiosteoporotic effects of CO have been investigated *in vivo* ([@B4]). Administration of CO prevented trabecular bone loss in the tibia of ovariectomized rats by inhibiting bone resorption and increasing serum phosphorus, calcium, and OPG levels, without affecting the body or uterus mass ([@B4]). The serum levels of bone resorption related makers, DPD/Cr, TRAcP, ACTH, and corticosterone were decreased following CO administration ([@B4]). CO may also enhance bone formation upon induction during wound healing ([@B172]).

Curculigoside (CCG, a phenolic glycoside) is the main bioactive compound of CO and appears to have both osteogenic and antiosteoclastic effects ([@B89]). A recent *in vitro* study evaluated the effect of CCG on osteogenic differentiation of human amniotic fluid-derived stem cells (hAFSCs) and found that CCG up-regulated osteogenic activity in a dose-dependent manner, including increased expression of osteopontin (OPN) and Collagen I, increased ALP activity and calcium deposition ([@B89]). Furthermore, the ratio of OPG to RANKL increased, indicating that osteoclastogenesis was inhibited. The simultaneous up-regulation of β-catenin and Cyclin-D1 indicate that these effects appear to be mediated *via* the Wnt/β-catenin signalling pathway ([@B89]). The *in vitro* effect of CCG on osteogenic differentiation has also been investigated in relation to BMSCs, and the data indicate that CCG may promote the proliferation and osteogenic differentiation of BMSCs ([@B134]).

The antioxidant properties of CO are also thought to be attributable to CCG, and may play a critical role in attenuating osteoporosis pathophysiology ([@B163]). The antioxidant protective effects of CCG have therefore been investigated in rat calvarial osteoblasts exposed to hydrogen peroxide (H~2~O~2~), and findings indicate that CCG significantly reduce the cytotoxic effects of H~2~O~2~ by reducing the production of reactive oxygen species (ROS) by osteoblasts, and recovering the levels of osteoblast differentiation markers, including ALP, calcium deposition, and runt-related protein 2 (Runx2) ([@B163]). CCG has also been shown to protect rat calvarial osteoblasts from dexamethasone (DEX) induced cytotoxicity by regulating osteoblast proliferation, differentiation, and proinflammatory cytokine levels ([@B211]). The effects of DEX on the levels of osteoblast differentiation markers, including ALP, OPG, β-catenin, and RANKL was reversed, indicating that CCG may be a suitable compound for the treatment of osteoporosis ([@B211]). Accordingly, metabolic analysis indicates that CCG *via* its main metabolite, M2, could produce these antiosteoporotic effects ([@B153]).

Further *in vitro* and rat calvarial studies have shown that compounds isolated from CO appear to have antiosteoporotic properties, including the promotion of osteoblast proliferation and differentiation, increased bone-forming activity, and the inhibition of osteoclastic bone resorption. The bioactive compounds isolated from MO include novel homogeneous polysaccharides, COP90-1 and COP70-3, and phenolic glycosides ([@B54]; [@B166]; [@B159]; [@B160]).

Briefly, the promotion on osteogenesis of C. *orchioides* might be the beneficial effect leading to attenuation of osteoporosis, and the inhibition of reactive oxygen species is a great property of this medicine. Additionally, some compounds isolated from CO exhibit the suppression of osteoclastic bone resorption. Further research is necessary to discover the molecular mechanisms, signalling pathways, and bioactive constituents of CO; and to determine the molecular basis of the potential relationship between the antioxidant effects of CCG and osteoporosis pathophysiology in osteoclasts and osteoblasts.

*Psoralea corylifolia* (L.) Medik {#s2_3}
---------------------------------

*Psoralea corylifolia* (L.) Medik (PC, "Bu Gu Zhi") is widely used in Asia for medicinal purposes; the dried ripe seeds are the active component of the plant. PC is used in Chinese pharmacopoeia and TCM formulas for the treatment of skin diseases, cardiovascular disease, nephritis, and osteoporosis ([@B204]). The primary bioactive compounds of PC are coumarins (e.g., psoralen), flavonoids (e.g., neobavaisoflavone, bavachalcone, bavachin, and corylin), and meroterpenes (e.g., bakuchiol) ([@B204]). Additional components of PC have immunoregulatory, antioxidant, and neuroprotective properties for the treatment of Parkinson's disease ([@B55]). PC may also have therapeutic potential for the treatment of prostate cancer ([@B85]).

The potential beneficial effects of PC in relation to osteoporosis treatment has been evaluated in animal models ([@B110]; [@B148]). Administration of PC was found to decrease urinary calcium secretion and decrease serum calcium in OVX rats, resulting in improvements in BMD and bone formation, and may have therapeutic potential for the treatment of postmenopausal osteoporosis ([@B148]). Complementary investigation indicates that PC may have therapeutic benefits for the broader treatment of bone pathological conditions, including bone fracture, osteomalacia, and osteoporosis ([@B110]). Furthermore, two compounds of PC, bavachin (BA, a flavonoid), and bakuchiol (BK, a meroterpene) have been shown to have osteoanabolic activity by inducing osteoblast differentiation. And maybe bioactive components of PC that could provide protection against post-menopausal bone loss ([@B84]; [@B170]). Bavachin appears to be more effective in stimulating cell proliferation, whereas bakuchiol appears to have a greater effect on osteoblast differentiation ([@B73]). The molecular structures of bavachin and bakuchiol that hypothetically produced variation in the osteogenic effects between these two and additional compounds of PC depending on its position, is a prenyl group side chain ([@B73]). Further research is needed to investigate the effect of changing the position of the prenyl group on the strength of osteoblast activity of PC compounds ([@B73]). The osteogenic effects of BA and BK appear to be produced by up-regulation of the Wnt signalling pathway, and produce increased ALP levels, Ca serum concentration, and BMD ([@B84]; [@B170]). Further *in vitro* findings suggest that BK inhibits RANKL-induced osteoclast differentiation and bone resorption by disrupting the AKT and AP-1 signalling pathways ([@B6]).

Psoralen (PSO), an active coumarin-compound of PC, is reportedly a promoter of bone mass and has been tested in a rodent ovariectomized model of osteoporosis ([@B189]). Findings showed that PSO produced an increase in trabecular thickness, and up-regulated osteogenic markers, including osteocalcin and ALP ([@B189]). Furthermore, the *OVX*-induced gene expression profile was reversed by PSO treatment, appearing to be mediated *via* the Notch signalling pathway, and resulted in regulation of the differentiation of bone mesenchymal stem cell, thus indicating the osteogenic potential of PSO for the treatment of postmenopausal osteoporosis ([@B189]). In vitro findings indicate that PSO may also attenuate osteoclast differentiation and bone resorption *via* inhibition of the AKT and AP-1 signalling pathways ([@B6]).

Neobavaisoflavone (NBIF), an isoflavone compound of PC, may also have an osteogenic activity that could be applied for the treatment of bone fractures, osteomalacia, and osteoporosis ([@B24]). In vitro findings demonstrated that NBIF enhanced osteogenesis in a concentration-dependent manner by increasing ALP activity, increasing the expression of bone-specific matrix proteins (including type I collagen, Col-I), increasing osteocalcin and bone sialoprotein levels, up-regulating the expression of Runx2 and osterix (OSX), and by the formation of bone nodules ([@B24]). Further experiments indicate that inhibition of the p38 receptor results in the inhibition of NBIF osteogenic activity, and, that NBIF also increases the active phosphorylated level of p38 in a concentration-dependent manner. Therefore, the osteogenic activity of NBIF appears to be mediated by activation of the p38-dependent signalling pathway ([@B24]).

The flavonoid compound, bavachalcone, isolated from PC may be an effective herbal compound to inhibit osteoclast activity and attenuate osteoporosis-induced bone loss ([@B123]). Bavachalcone was found to inhibit osteoclast formation of primary culture osteoclast precursor cells, *in vitro* ([@B123]). In the presence of bavachalcone, the activity of the osteoclast differentiation factor, NFκB (RANKL), was reduced, leading to inhibition of osteoclastogenesis *via* suppression of transcription factors, c-Fos, NFATc1, and by blocking MEK, ERK, and Akt signalling ([@B123]).

Taken together, these findings suggest that *P. corylifolia* appears to be an important therapeutic agent in Chinese medicine for the treatment of osteoporosis. The compound of bakuchiol should be studied more deeply for it appears to have dual properties of promoting osteogenic activity and ameliorating osteoclastic bone resorption to attenuate osteoporosis, and it has a higher promotion on osteoblast differentiation than bavachin ([@B73]; [@B6]). Further research is needed to isolate, characterize, and investigate the effect of variation of the molecular structure of the active compounds of PC on osteoblast and osteoclast activity, including their biochemical effects and signalling pathways.

*Eucommia ulmoides* Oliv. {#s2_4}
-------------------------

*Eucommia ulmoides* Oliv. (EU, "Du Zhong") is a plant, and the dried bark of EU is used in TCM and as a food source ([@B50]). EU has pharmacological properties as an antioxidant, anti-inflammatory, antimicrobial, anticancer, cardioprotective, and neuroprotective agent that have been applied for the treatment of cardiovascular disease, sexual dysfunction, cancer, metabolic disease, neurological disease, rheumatoid arthritis, osteoarthritis, and diabetes ([@B180]; [@B50]; [@B152]; [@B23]). The bioactive compounds of EU include lignans, iridoids, phenolics, steroids, and flavonoids ([@B50]). Additional studies have found that the EU could also be effective in the treatment of osteoporosis.

Du Zhong cortex extract (DZCE) has been evaluated to investigate the potential protective benefits against lead-induced, estrogen deficiency-induced, and disuse-induced osteoporosis ([@B201]; [@B122]; [@B128]). In a rodent model of lead acetate-induced bone loss, DZCE attenuated the loss of BMD of the lumbar spine and femur, and restored serum calcium, phosphorous, ALP, osteocalcin, and RANKL to normal levels ([@B128]). Furthermore, antiosteoclastic activity was indicated by the effect of DZCE on adjusting the serum OPG/RANKL ratio to normal values ([@B128]). In an OVX-rat model of estrogen deficiency-induced osteoporosis, higher doses of DZCE prevented further deterioration of the biomechanical properties of the femur, including maximum stress and Young's modulus, which was accompanied by attenuation of loss of BMD ([@B201]). These findings were supported by micro-CT analysis indicating that the parameters of BMD and bone thickness were improved by higher doses of DZCE, and because the levels of bone turnover markers, osteocalcin, ALP, and deoxypyridinoline (DPD) were decreased ([@B201]). Total lignans (TL) extracted from EU-cortex, was also found to inhibit the loss of bone mass due to estrogen deficiency-induced osteoporosis in a rodent model ([@B202]). In vivo findings demonstrated improvements in the biomechanical quality of the femur, in terms of maximum stress and Young's modulus, and micro-CT analysis showed prevention of further trabecular microstructural degradation ([@B202]). In vitro findings showed that TL promoted the proliferation and differentiation of osteoblasts; and inhibited osteoclastogenesis, by an increase in OPG and decrease in RANKL expression ([@B202]). In a rodent disuse-induced osteoporosis model, DZCE treatment improved bone strength and prevented trabecular microstructural degradation, and reduced the levels of bone turnover markers, including TRAcP, DPD, and OC ([@B122]). Additional findings in rodents indicate that EU could promote longitudinal bone growth by increasing chondrogenesis of the tibial growth plate, and increasing levels of BMP-2 and IGF-1 ([@B61]). Taken together, these results suggest that DZCE may provide effective treatment for osteoporosis by attenuating bone loss, both by the formation of bone, and by inhibiting osteoclastic bone resorption; and may promote longitudinal growth of the long bones.

5-(hydroxymethyl)-2-furaldehyde (5-HMF) is a bioactive compound isolated from Eucommiae Cortex that has been shown to promote osteogenesis and inhibit adipogenesis ([@B146]). In vitro findings demonstrated that 5-HMF induction of BMSCs in normal medium up-regulated the expression of osteogenesis-markers (ALP, COL1alpha1, OC, and OPN), and that 5-HMF decreased the expression of adipogenesis-markers (PPARγ, FABP4, C/EBPα, and LPL) by BMSCs in adipogenic induction medium ([@B146]). Furthermore, mineralized nodule formations were produced by BMSCs induced by 5-HMF cultured in both normal and adipogenic-inducing medium, indicating the potent osteogenic, antiadipogenic, and antiosteoporotic properties of 5-HMF ([@B146]). Further research is necessary to investigate the molecular mechanisms involved with the osteogenic, and potential pro-osteoblastic and antiosteoclastic effects of 5-HMF and additional bioactive components of EU-cortex ([@B39]).

The leaves and seeds of EU may also be of potential benefits for the treatment of osteoporosis ([@B78]; [@B203]). In a combined estrogen deficiency-induced osteoporosis and obesity rodent model, Eucommia leaf extract (ELE) treatment decreased body weight and BMI, and increased tibial and femoral BMD, and increased bone strength, which appeared to be the effects of restoring bone metabolism, respective of bone formation, and adsorption ([@B203]). Further rodent study indicates that administration of total glycosides from Eucommia ulmoides seed (TGEUS) could enhance the BMD and the microarchitecture parameters of the femur in healthy rats ([@B78]). Iridoid compounds isolated from the leaves of the EU may be the bioactive components that render the therapeutic effects ([@B143]).

Taken together, we think that the herb of *E. ulmoides* is a great medicine to treat bone loss diseases, for many parts of EU including the cortex, leaf, and seed, might have potential therapeutic benefits for the treatment of osteoporosis, as depicted above ([@B78]; [@B203]; [@B128]). Furthermore, *in vivo* and *in vitro* findings show that they provide effective treatment for osteoporosis by increasing bone strength and preventing trabecular microstructural degradation, promoting osteogenesis, and inhibiting bone resorption. Usually, the cortex is the major part of the EU that is used to treat bone, cardiovascular, and sexual diseases. Based on the positive evidence and effects of the leaf and seed, more research is needed to isolate and characterize the bioactive molecules of EU, and compare the effects between cortex, leaf, and seed for the treatment of osteoporosis, including the mechanisms that produce the potential therapeutic effects among them.

*Dipsacus inermis* Wall. {#s2_5}
------------------------

*Radix Dipsaci* (RD, "Xu Duan") is the dried roots of *Dipsacus inermis* Wall., and it is used in Chinese medicine to strengthen bone ("Xu Duan" means "to promote the growth of bones to correct bone fractures"). Recently, studies have reported that RD may be a beneficial bone formation agent to treat osteoporosis ([@B97]; [@B120]; [@B91]).

The bone formation properties that may provide therapeutic benefit for the treatment of osteoporosis have been investigated in recent animal studies. In ovariectomy-induced postmenopausal rodent models, RD treatment prevented the loss of bone mass and trabecular microstructural degradation, and improved bone strength ([@B97]; [@B91]). These results may be attributed to altered bone remodeling, as evidenced by a decrease in the level of bone turnover markers, including ALP, OC, and DPD. Furthermore, the effects of ovariectomy on OPG and RANKL levels of osteoblasts and BMSCs were reversed by treatment with RD (OPG levels increased and RANKL levels decreased), indicating the osteogenic effect of RD on molecular biomarkers ([@B91]). The osteogenic effect of the dichloromethane fraction of RD on BMSCs has been demonstrated *in vitro* by the formation of calcified nodules, increased ALP activity, increased expression of bone sialoprotein (BSP) and OC ([@B57]). An active single compound isolated from the dichloromethane fraction of RD, hederagenin 3-O-(2-O-acetyl)-α-L-arabinopyranoside, significantly increased ALP, OC, and BSP levels ([@B57]). A hindlimb unloading rodent model of osteoporosis investigated the effect of RD treatment on BMD and bone microarchitecture, and showed that the biomechanical properties were enhanced ([@B117]). Oral administration of RD improved the mechanical strength of bone, BMD, BMC, and bone turnover markers, including urinary calcium and phosphorus excretion. Micro-CT analysis showed that RD prevented trabecular microstructural degradation, improved the bone volume fraction, and improved tissue mineral density and content ([@B117]). Healthy rats fed with Radix Dipsaci extract (RDE) showed an anabolic systemic skeletal effect by increased bone density and altered bone histomorphology ([@B173]). An increase of bone trabeculae of 11.82% was measured, indicating that bone density was increased, and the bone histomorphology has also been improved by the enhancement of BV/TV (increased 4.5%), and improvements in BS/TV, Tb.N, and the reduction in Tb.Sp ([@B173]). Taken together, these findings suggest that RD may provide beneficial therapeutic effects for the treatment of osteoporosis.

Further studies of the bioactive components of RD indicate that several compounds, including saponins and iridoid glycosides extracted from RD and may produce biological effects ([@B57]; [@B147]). The antiosteoporotic effect of RD total saponins (RTS) may be related to its effect on osteoblast and osteoclast cells ([@B120]; [@B118]). Oral administration of RTS has been shown to prevent OVX-induced loss of bone mass in rats, indicated by decreased levels of bone turnover markers, including urinary calcium, and phosphorous excretion, and by increasing the biomechanical strength of bone and preventing trabecular microstructural degradation ([@B120]). In vitro findings determined that RTS promoted osteoblastic cell maturation and differentiation, increased ALP and OC levels, and increased the synthesis of BMP-2, leading to increased bone formation ([@B120]; [@B118]). The positive effect of RTS on osteoblast cells appears to be mediated *via* the BMP2/mitogen-activated protein kinase (MAPK)/Smad1/5/8-dependent Runx2 signalling pathway ([@B118]). Furthermore, RTS inhibited osteoclastogenesis by increasing the expression of OPG and decreasing the expression of NF-κB (RANKL) ([@B120]). Additionally, asperosaponin VI is a saponin isolated from RD that has been shown to promote the proliferation, differentiation and mineralization of osteoblastic cells, and these effects appear to be mediated by BMP-2 synthesis, and activation of p38 and ERK1/2 signalling ([@B119]).

Collectively, these findings suggest that RD appears to provide beneficial therapeutic effects for the treatment of osteoporosis, including attenuating bone loss and increasing bone strength and quality, that may be attributed to their improved physiological bone remodelling *in vivo*. At cellular and molecular levels, the RD and its bioactive components appear to promote osteoblast differentiation, proliferation, maturation, and mineralization, and may inhibit osteoclastogenesis. The bone research-related amimal models were rich in these studies including ovariectomy-induced postmenopausal rodent models, hindlimb unloading model, and healthy rats to detect the bone metabolism. While some treatment ingredients of Radix Dipsaci, such as ethyl alcohol or crude extractions, are not well studied. It is necessary for further research to identify the efficient compounds and to develop the therapeutic potential and mechanism of RD in the treatment of osteoporosis.

*Cibotium barometz* (L.) J.Sm {#s2_6}
-----------------------------

*Cibotium barometz* (L.) J.Sm (CB, "Gou Ji") is well-known in TCM and its hairs are a staple ingredient used in ointments, such as an antihaemorrhagic agent for wound healing poultices ([@B175]). The rhizome of CB contains anti-inflammatory properties and is used in the treatment of diseases including rheumatism, lumbago, sciatica, and dysuria in the aged ([@B175]). CB is thought to have properties that nourish bone and improve gonadal function. And it is frequently used in herbal remedies for the treatment of osteoporosis ([@B210]).

Due to the potential benefits of CB for the treatment of osteoporosis, research has been performed to determine the effects of CB *in vivo* and *in vitro*. In a rodent model of post-menopausal estrogen-deficiency-induced osteoporosis, daily administration of the extract of CB (CBE) was shown to prevent femur total BMD loss in OVX-rats, which appeared to be associated with a decrease in skeletal remodeling, as evidenced by decreased levels of bone turnover markers OC, ALP, DPD, and urinary excretions of calcium and phosphorous ([@B210]). Furthermore, the CBE treatment also appeared to enhance bone strength and prevent trabecular microarchitectural degradation as determined by improvements in micro-CT microstructural parameters. When compared with the untreated model rats, CBE treatment significantly increased the bone maximum stress, energy, and Young's modulus of OVX rats ([@B210]). CBE treatment performed favourably in comparison with estrogen-therapy in terms of its effect on body weight and uterine weight ([@B210]). Additional *in vitro* experiments have been performed to evaluate the potential effectiveness of the constituents of the rhizome of CB in the treatment of osteoporosis ([@B113]; [@B182]). Findings from these experiments indicate that these CB-rhizome constituents could promote the proliferation and differentiation of rat osteoblasts, and thus be potential therapeutic agents for the treatment of osteoporosis ([@B182]). Furthermore, compounds isolated from CB-rhizome appeared to inhibit osteoclastogenesis from primary bone marrow macrophages (BMMs) when cultured in an inductive medium, without any adverse effects on the viability of precursor BMM cells ([@B113]).

Therefore, evidence suggests that CB could be used as an effective therapeutic agent for the treatment of osteoporosis. The ingredients of CB in some research were still not very clear or definite, which are obtained by ethanol extraction from the dried and crude *C. barometz* ([@B210]). Further research is needed to isolate and characterize the bioactive constituents of CB, and to determine the molecular mechanisms and signalling pathways by which they produce therapeutic effects.

Velvet Antler {#s2_7}
-------------

*Velvet Antler* (VA, "Lu Rong") is the precalcified cartilaginous antler, in TCM commonly obtained from the Silka deer and Red deer, that is used as an effective agent to strengthen bone and for the improvement of immune health, physical strength, and sexual function ([@B199]; [@B141]). Velvet antlers regenerate annually in mammals, and ingestion of VA is thought to confer similar benefits upon the consumer ([@B37]). Both VA and its close relative, deer antler base, are designated medicinal products in the Chinese Pharmacopoeia ([@B174]). The bone-health promoting properties of VA has been investigated in relation to the treatment of bone diseases including osteoporosis and osteonecrosis ([@B199]; [@B168]).

The effectiveness of VA for the treatment of postmenopausal estrogen deficiency-induced osteoporosis has been investigated using rodent models ([@B185]; [@B150]; [@B199]). Total velvet antler polypeptides (TVAP) administered to OVX-rats were found to prevent bone loss and improve BMD, BMC, and bone microarchitecture, which appeared to be associated with inhibition of IL-1 and Il-6 ([@B199]). Furthermore, natural velvet antler polypeptides (nVAP) and synthetic-VAP (sVAP) promoted the proliferation of cartilage and osteoblast-like cells, and inhibited the activity of IL-1α secreted from THP-1 monocytic cells *in vitro*, indicating that TVAPL and sVAP may be potential therapeutic agents for the treatment of postmenopausal osteoporosis ([@B199]). Both VA and VA-blood can be used in TCM to tonify and invigorate bones and tendons, and the combination of middle sections of VA and VA-blood (VAM-B) is thought to have superior pharmacological effects ([@B150]). In OVX-rats, treatment with VAM-B improved body weight, and increased the strength of the vertebra and femur, and improved tibial trabecular microarchitecture, which was accompanied by a decrease in ALP levels. The results supported the therapeutic use of VAM-B for the treatment of postmenopausal osteoporosis ([@B150]). Additional research has shown that oral administration of VA-blood to OVX-rats could attenuate reduced BMD of the lumbar vertebra and femur, and normalize serum levels of insulin-like growth factor -1 (IGF-1) and testosterone ([@B185]).

Interestingly, the effect of fermentation on the bone formation capability of VA was investigated *in vitro* ([@B64]). Findings indicated that both non-fermented antler (NFA) and fermented antler (FA) treatment increased the proliferation of osteoblasts and bone matrix proteins, including type I collagen and BSP ([@B64]). Moreover, FA showed enhanced osteoblast proliferation, increased ALP activity, and increased mineralization compared to NFA and, therefore, the fermentation process may enhance the bone-forming effects of antler ([@B64]). Furthermore, the effect of fermentation on antiresorptive activity was investigated *in vitro*, and it appears that the fermentation process may improve the capability of VA to inhibit osteoclast differentiation and signalling activity ([@B16]). Findings indicate that the extract of FA inhibited RANKL-induced osteoclast differentiation from BMMs by downregulating the expression and activity of NFATc1, which was associated with inhibition of phospholipase Cγ2 (PLCγ2), a signalling molecule known to affect NFATc1 transcriptional activity ([@B16]). Thus, research suggests that FA extract may inhibit osteoclastic activity *via* disrupting PLCγ2-NFATc1 signalling, and may provide therapeutic benefit for the treatment of osteoclast-related bone diseases, including osteoporosis ([@B16]). Furthermore, *in vitro* studies have shown that the chloroform extract (CE-C) of deer antler appears to inhibit osteoclast differentiation by suppressing the activation of extracellular signal-regulated kinase (ERK), protein kinase B (PKB/Akt), the inhibitor of kappa B (I-κB), which would be increased by RANKL under osteoporosis conditions ([@B79]). CE-C also appears to inhibit the bone resorption activity of osteoclasts and disrupt the actin rings, leading to osteoclast apoptosis ([@B79]). Taken together, these findings suggest that VA and CE-C may be effective compounds for the treatment of osteoporosis.

Further research has compared the osteogenic capacity of VA from different sections of antler on longitudinal bone growth and osteoporosis ([@B149]; [@B59]). In vivo and *in vitro* findings indicate that VA promotes longitudinal bone growth in adolescent rats through enhanced BMP-2 expression, osteogenic gene expression, including collagen, ALP, and OC, and by promoting the proliferation, differentiation, and mineralization of osteoblast-cells ([@B59]). The osteogenic effects of VA appear to decrease from the upper or distal sections to the basal sections of antler ([@B149]; [@B59]).

Taken together, these findings indicate that VA appears to contain properties to strengthen bone, promote bone growth, and may provide therapeutic benefit for the treatment of osteoporosis by the bone formation and antiresorptive activity. Interestingly, research by Kim and Tseng et al. indicates that the basal sections of antler should be the prior selection for the better osteogenic effects when applied for the treatment of osteprorosis clinically. Further research is needed to identify and characterize the bioactive components of different sections of VA and the molecular signalling mechanisms that mediate their therapeutic effects, under the influence of varying preparation conditions.

*Cistanche deserticola* Y.C.Maf {#s2_8}
-------------------------------

*Cistanche deserticola* Y.C.Maf (CD, "Rou Cong Rong") is used in TCM for the treatment of kidney deficiency, sexual dysfunction, female infertility, and constipation ([@B33]). Recent reports suggest that CD could promote male fertility, and may attenuate tinnitus in patients with chronic nephritis, in addition to providing effective treatment for osteoporosis ([@B53]; [@B33]; [@B30]).

*In vivo* studies using rodent models of postmenopausal estrogen deficiency-induced osteoporosis have shown that Cistanches deserticola-extract (CDE) could provide therapeutic benefits for the treatment of osteoporosis ([@B81]; [@B82]). Findings indicate that CDE could dose-dependently enhance the femoral BMD and BMC in OVX rats, and improve biomechanical femur parameters of loading and autobreak including maximum load, maximum displacement, and stress ([@B81]). In comparison with OVX rats, CDE-treatment rats showed biochemical differences including decreased blood calcium, zinc, and copper levels ([@B81]). Further *in vivo* investigation of the molecular mechanisms behind the antiosteoporosis effect of CDE indicate that the attenuation of bone degeneration is associated with the regulation of genes involved with bone metabolism, including *Smad1*, *Smad5*, *TGF-β1*, and *TIEG1* ([@B82]). Additionally, *in vivo* investigation of the effects of CD compound, Cistanoside, on OVX rats indicates that CD may contain both osteogenic and antiosteoclastic properties ([@B183]). In addition to increasing bone strength, BMD, and improving trabecular microstructure, Cistanoside may also decrease the activity of bone resorption markers including TRAP, DPD, and cathepsin K ([@B183]). These effects appear to be mediated by down-regulation of TNF-receptor associated factor 6 (TRAF6), which downstream mediates both the inactivation of NF-κB, to inhibit osteoclast activity, and the stimulation of the PI3K/Akt osteogenic pathway ([@B183]).

*In vitro* studies have demonstrated that CD may induce bone formation for the treatment of osteoporosis ([@B68]; [@B72]). CD extract increased the expression of ALP, BMP-2, and OPN, and increased bone mineralization by cultured osteoblast cells ([@B72]). Echinacoside (ECH), a phenolic compound isolated from CD, appears to promote bone formation activity by cultured osteoblast cells, including increased cell proliferation, ALP activity, OC levels, and mineralization, which may be associated with increasing the OPG/RANKL ratio ([@B68]). Correspondingly, *in vivo* findings support the positive dose-dependent effects of ECH for the treatment of osteoporosis in OVX rats ([@B67]). Following ECH treatment for 12 weeks at the doses of 90 mg/kg and 270 mg/kg, the femur BMD was significantly enhanced ([@B67]). Furthermore, the histomorphological and micro-CT analysis indicated that the deteriorated microarchitecture and biomechanical parameters had been reversed, and that the cortical bone thickness, osteoblasts number, and trabecular thickness were enhanced ([@B67]). Further research suggests that CD derived compounds may also decrease osteoclastic bone resorption by inhibiting osteoclastogenesis, attenuating RANKL activity, and disabling NFAT and MAPK ([@B137]).

Collectively, these findings suggest that CD may contain properties that are potentially effective for the treatment of postmenopausal osteoporosis. Though the compound of Cistanoside may act as a good representative of *Cistanches deserticola* with the interesting study that it could possess both osteogenic and antiosteoclastogenesis properties, further research is necessary to isolate and characterize the bioactive constituents of CD and to investigate their potential osteogenic and antiresorptive effects, and the molecular signalling pathways affected by Cistanches herb in relation to osteoporosis.

*Cuscuta chinensis* Lam. {#s2_9}
------------------------

The seed of *C. chinensis* Lam. (CC, "Tu Si Zi") is one of the commonly used herbs in Chinese medicine for the enhancement of sexual function, vision, and birth control ([@B25]). The biological activity of CC includes skin and liver protection, immune regulation, neuroprotection, antioxidant, and anti-inflammatory properties ([@B25]). Current research is investigating the effectiveness of CC for the treatment of osteoporosis ([@B25]).

*In vivo* and *in vitro* experiments indicate that the bioactive compounds of CC that appear to be effective against osteoporosis are kaempferol, hyperoside, and campesterol ([@B190]; [@B186]; [@B121]). In a rodent model of postmenopausal estrogen deficiency-induced osteoporosis, kaempferol (isolated from the seeds of CC), increased the femoral BMD and Young's modulus of OVX rats as compared to untreated controls, which was accompanied by reduced bone turnover, increased bone tissue volume ratio and increased trabecular bone perimeter ([@B121]).

*In vitro* studies showed that the extract of CC could dose-dependently increase osteoblast-like cell proliferation and mineralization, and that this was accompanied by enhancing ALP activity, increased collagen synthesis, and BMP-2 expression ([@B184]). Furthermore, CC appears to protect osteoblast cells from tertiary butyl hydroperoxide (TBHP) oxidative stress-induced apoptosis, possibly due to its antioxidant activity and function *via* mitochondria-dependent pathways ([@B34]). Additional *in vitro* evidence has demonstrated that CC may promote the proliferation and differentiation of osteoblast from their precursor cells to induce mineralized nodule formation and decrease osteoclastic activity as indicated by TRAcP ([@B190]).

Taken together, these findings indicate that the osteogenic, antioxidant, and antiosteoclastic properties of CC may provide therapeutic benefit for the treatment of osteoporosis. Although the evidence has indicated the promotion on osteogenesis and the inhibition on bone resorption by the compounds, kaempferol, and campesterol, their respective functional mechanisms were still not well studied, not like the researches in [@B184] and [@B34]. However, the compounds in Yang and Gao *et al.* were the aqueous extraction, the certain compound were not well known, therefore, further research is necessary to isolate and characterize the bioactive components of *C. chinensis* including their therapeutic potential and molecular mechanisms for the treatment of bone diseases, including osteoporosis.

*Cnidium monnieri* (L.) Cusson {#s2_10}
------------------------------

*Cnidium monnieri* (L.) Cusson (CM, "She Chuang Zi") is a commonly used herb in Chinese medicine to alleviate pain and inﬂammation, improve sexual potency, for the treatment of skin-related diseases and to improve bone strength ([@B80]). Over 300 compounds have been isolated from CM and the main bioactive constituents appear to be coumarins compounds ([@B80]). Further research has reported the potential application of CM for the treatment of Parkinson's disease, cancer, and osteoporosis ([@B200]; [@B46]; [@B164]).

Coumarins extracted from CM have been shown to produce potentially beneficial therapeutic effects for the treatment of osteoporosis ([@B107]; [@B200]; [@B109]). The chloroform fraction of CM was found to promote osteoblast activity and three coumarins (osthole, bergapten, and imperatorin) were subsequently isolated for further analysis ([@B107]). In neonatal rodent calvaria culture, osthole was shown to promote osteoblast proliferation and ALP activity, and to inhibit bone resorption by decreasing the formation, differentiation, and TRAcP activity of rat marrow osteoclasts, thus indicating that CM may have potential therapeutic benefits for the treatment of osteoporosis ([@B107]).

Further *in vivo* and *in vitro* investigations of the potential effectiveness of osthole for the treatment of osteoporosis have been performed ([@B208]). Analysis of findings from a mouse femur fracture model indicated that osthole enhanced fracture repair, bone regeneration, and increased bone strength as compared to untreated controls ([@B208]). In vitro findings determined that osthole promoted osteogenesis by osteoblast cells in a time- and concentration-dependent relationship by increasing osteogenic differentiation, ALP activity, and calcium nodule formation ([@B109]; [@B208]). In addition, osthole appeared to induce osteogenesis *via* the BMP-dependent signalling pathway as determined by the increased expression of osteogenic-related genes *BMP-2*, *Runx2*, *osterix (Osx)*, and *OCN*, and by the observed inhibition of osteogenesis resulting from antagonization by the BMP-antagonist, noggin ([@B109]; [@B208]). Further mechanistic analysis demonstrated that the osteogenic effects of osthole appear to be mediated *via* activation of the cAMP/CREB signalling pathway, which appeared to target the transcription factor, Osx ([@B208]). Additional *in vivo* evidence suggests that osthole may provide therapeutic benefit for the treatment of postmenopausal osteoporosis, that may be as effective as 17β-estradiol ([@B75]). In OVX rats, both osthole and 17β-estradiol inhibited estrogen deficiency-induced cancellous bone loss, and increased the biomechanical maximal load of the femoral neck ([@B75]). Osthole could also suppress the urinary deoxypyridinoline (DPD) level of OVX rats. However, osthole did not appear to reduce serum OC levels, nor effects on body or uterus weight as was observed in the 17β-estradiol group, thus indicating that the therapeutic benefits of osthole for the treatment of postmenopausal osteoporosis may not be mediated by the estrogen pathway ([@B75]). Additionally, in healthy rats, osthole was shown to increase total body and femur BMD, trabecular microstructural parameters, and biomechanical properties of maximum load and Young's modulus, which were accompanied by increased serum OC and TRAcP levels ([@B7]). Taken together, these findings suggest that osthole may provide potential therapeutic benefit for the treatment of osteoporosis by promoting osteogenic activity and attenuating bone resorption. Further research is necessary to characterize the antiosteoporosis effects of osthole more extensively.

*In vitro* evidence indicates that imperatorin may also have anabolic potential by stimulating the proliferation and osteogenic activity of MCF-7 cells, and ALP activity of Saos-2 osteoblast cells, possibly by exerting estrogenic properties *via* the estrogen-receptor pathway ([@B51]). Further research is necessary to investigate the potential therapeutic effects for the treatment of osteoporosis *in vivo*.

Bergapten has also been tested for the potential biopharmacological properties that may be of therapeutic value for the treatment of bone disease, including osteoporosis ([@B10]). In vivo investigation of the potential effects of bergapten against ovariectomy-induced osteoporosis in mice, and *in vitro* analysis of RANKL-induced osteoclastogenesis was performed ([@B10]). Findings indicated that bergapten appears to inhibit osteoclastic bone resorption and attenuates RANKL-induced osteoclastogenesis, which is mediated *via* disruption of the NF-κB and JNK signalling pathways ([@B10]). Furthermore, bergapten effectively reduced the activity of NFATc1 and c-fos (osteoclastogenesis associated transcription factors) which decreased the expression of osteoclast differentiation-related genes, and attenuated osteoclastogenesis by BMMs and RAW264.7 cells without any cytotoxic side-effects. Moreover, bergapten disrupted the formation of F-actin rings, which are implicated in bone resorption activity ([@B10]).

Overall, *in vivo* and *in vitro* evidence suggests that coumarin compounds isolated from CM, mainly osthole and bergapten, may produce bio-pharmacological effects for the treatment of osteoporosis by acting to increase bone formation and to decrease bone resorption. Interestingly, the level of serum OC was not affected in OVX rats, while it was enhanced by osthole in the healthy rats, indicating that more studies and attention should be paid to the effects of osthole on serum OC. Further research is necessary to extensively characterize the bioactive effects of CM that render potential therapeutic benefit for the treatment of osteoporosis.

*Epimedium brevicornum* Maxim {#s2_11}
-----------------------------

*Epimedium brevicornum* Maxim (EBM, "Yin Yang Huo") is a very popular natural drug been traditionally used to treat bone diseases, pregnancy, and gonad dysfunction in Chinese medicine for thousands of years. It could relieve postmenopausal symptoms and inhibit osteoporosis and other bone loss diseases, while few hyperplastic effects on the uterus were found. These antiosteoporotic effects may be related with the estrogenic properties by the intrinsic phytoestrogens including some of the flavonoids, lignans, sterols, etc. ([@B151]; [@B181]). In the systems pharmacology study, there are 77 components in *Epimedium* possessing the analogous structure to estrogen ([@B181]). Many of these phytoestrogenic compounds have the beneficial effects to inhibit osteoporosis, including icariin, epimedin A, epimedin B, epimedin C, icariside II and icaritin, epimedoside C, baohuoside I, baohuoside II, etc. ([@B108]; [@B49]; [@B195]; [@B95]; [@B154]; [@B92]). Among these ingredients, icariin is the main compound of *Epimedium brevicornum* Maxim. Now, there have been many studies and reviews focusing on its anabolic and anticatabolic effects. Certain studies found that icariin has better antiosteoporotic effects than other compounds ([@B103]; [@B165]). This review would emphatically introduce the potential effects of icariin to treat osteoporosis, being represented for *Epimedium brevicornum* Maxim.

Icariin, a prenylated flavonol glycoside, was one of the main effective compounds in *Epimedium*. With the instinct estrogen biosynthetic effect ([@B187]), it had potential osteogenic and antiosteoclastogenic effects *in vitro* and *in vivo*, and antiosteoporotic effects in clinical.

Recent *in vitro* studies have demonstrated that icariin could enhance the ALP activity, osteogenic differentiation and improve the maturation and mineralization of MSCs and osteoblasts including hFOB 1.19 cells, MC3T3-E1, UMR 106 cells ([@B12]; [@B111]; [@B29]; [@B5]; [@B83]). Icariin could also have a pronounced ability to promote the differentiation of osteoblast even with the absence of dexamethasone ([@B104]). Correspondingly, the mRNA expression of osteogenesis-related genes including *COL1a2*, *OSX*, *RUNX-2*, *BMP-2*, *Smad4*, *Notch2*, and *OPG/RANKL* ratio were significantly increased ([@B179]; [@B209]; [@B48]; [@B103]; [@B3]; [@B5]; [@B83]; [@B74]). Extra studies found that icariin treatment could significantly induce the activation of ERK, JNK, and p38 kinase, and their respective inhibitors would dramatically attenuate icariin-stimulated osteogenic effects. Ye et al. found that TAZ (the transcriptional coactivator with PDZ-binding motif) depletion could significantly block the promoting proliferation and osteogenic differentiation induced by icariin treatment ([@B191]). These studies indicated the involvement of Wnt/β-catenin-BMP2, Notch, MAPK, and RhoA-TAZ signalling pathways in the osteogenic effects by icariin ([@B138]; [@B176]; [@B191]). Additionally, the osteogenic differentiation ability of BMSCs from OVX rats would be significantly decreased compared with that in the sham operation group. While icariin treatment could act to protect and increase the osteogenic differentiation and mineralization *via* the estrogen pathway ([@B101]). Icariin could also protect osteoblasts cell cycle and suppress their apoptosis induced by oxidative stress. There was less production of reactive oxygen species and malondialdehyde, and more superoxide dismutase activity with the treatment of icariin ([@B68]). Therefore, icariin could effectively preserve potential osteogenic differentiation of the cells in hypoxic condition, with the increased levels of *RUNX-2*, *OSX*, and *BMP-2* gene expression, and the functions of ALP activity, and mineralized nodules ([@B68]).

Icariin not only stimulated osteogenic differentiation but also suppressed the osteoclastogenesis and inhibited bone resorption activity *in vivo*. It was found that icariin could effectively control the proliferation and differentiation of hemopoietic cells which could develop into osteoclasts at the concentration of 10 mM. With the exposure of icariin, the TRAP-positive multinuclear cells appeared to be less. The formed bone resorption pits were inhibited and the osteoclastogenesis-related expressions of *TRAP*, *RANK*, and *CTR* genes were controlled by icariin ([@B11]). Huang reported that icariin could suppress the bone resorption functions of osteoclasts *via* the affection on cytosolic free calcium, actin rings, and superoxide generation ([@B49]). The positive activities of TRAcP, and the activities of osteoclasts formation and bone resorption stimulated by LPS were diminished by icariin. Correspondingly, the synthesis of cyclo-oxygenase type-2, prostaglandin E2, hypoxia-inducible factor-1, and the activation of p38 and JNK were inhibited ([@B47]). Additionally, icariin could inhibit Ti particles-stimulated increase of RNA expressions of the RANKL, CTSK, TRAcP, and MMP9 in RAW264.7 cells. The expressions of IL-1β and TNF-α were increased induced by Ti particles of RAW264.7 cells had also been inhibited ([@B17]). These experiments indicate the potential inhibitory effects of icariin on the prevention of inflammatory bone loss diseases.

*In vivo* studies with OVX rats, the flavonoids treatment of Epimedium Brevicornum could increase the level of serum osteocalcin and decrease the TRAcP with the comparison to untreated rats. The micro-CT result indicated that the parameters of BMD, BV/TV, Conn.D, and other similar indicators in flavonoids-treated OVX rats were obviously better. The bone histomorphometric parameters of OS/BS, MAR, and BFR/BS were improved. In the mechanical testing, the OVX would induce the reduction of the failure force. However, it was effectively inhibited by flavonoids treatment. While no increase of uterus weight was found during the treatment progress ([@B196]; [@B126]; [@B83]). The experiments *in vivo* with C57BL/6 mice found that icariin could prevent decreased BMD and bone strength in femur by oestrogen deficiency after ovariectomy surgery ([@B111]). The ratio of OPG/RANKL expression in tibia has been improved ([@B111]). In the OVX rat experiment, orally treated rats with icariin at the concentration of 125 mg/kg body weight enhanced the activity of bone mineralization and formation, obtaining higher BMD, biomechanical, and histopathological parameters. And the decreased concentrations of Ca^2+^, P, and E~2~ in the serum were prevented ([@B114]). In the glucocorticoid-induced osteoporosis (GIOP) model study, icariin significantly attenuated the bone deteriorations, less BMD, hypocalcemia, and hypercalciuria of glucocorticoid positive group. The bone formation level of ALP, calcium, OCN, and fibroblast growth factor-23 in serum were increased. The bone resorption markers of carboxyterminal collagen cross-links, C-terminal telopeptide of type I collagen, and TRAP were reduced ([@B31]; [@B198]). The antiosteoporotic effects by icariin maybe act *via* involvement of the ERK, PI3K/Akt/GSK3b/β-catenin integrated signalling pathways ([@B31]; [@B198]). Liu et al. found that icariin had beneficial effects for osteoporotic rats *via* the inhibition of peroxisome proliferator-activated receptor γ (PPARγ) and Notch2 mRNA expression ([@B86]). And Ma et al. found that icariin appears to be a therapeutic drug to manage glucocorticoid-induced bone loss *via* the activation of microRNA-186-mediated suppression on cathepsin K ([@B105]). Additionally, icariin could significantly reduce particle-induced bone resorption by suppressing osteoclast formation ([@B132]). Oral administration of icariin improved the abilities of bone formation with higher BMD in the regenerated bone area during the distraction osteogenesis of mandibular, indicating the icariin might be a potential medicine could shorten the course and improve the activity of distraction osteogenesis ([@B169]).

In clinical, a double-blind placebo-controlled clinical trial showed that the flavonoids treatment (containing the compounds of icariin, daidzein, and genistein in Epimedium) possessed the beneficial ability to inhibit the serious bone loss in postmenopausal women. The BMD could be maintained at 12 and 24 months with treatment. However, no significant changes in serum estradiol or uterus tissue were found, indicating the safety to endometrium during the application ([@B197]).

Therefore, being the main ingredient of *E. brevicornum*, icariin could act as a potential useful medicine to affect the imbalance of bone metabolism by increasing osteogenesis and inhibiting bone resorption. More importantly, despite the low number of clinical trials with Chinese medicine compounds, and three kinds of flavonoids in the Epimedium treated group, it has effectively indicated the antiosteoporotic effects by *Epimedium Brevicornum Maxim* clinically. Numerous studies in this review based on osteoporotic animal models, osteoblasts and osteoclasts cells have deeply and consistently confirmed the potential effects and mechanisms by which icariin regulates bone metabolism to treat osteoporosis. Furthermore, high-quality clinical research is needed to test the antiosteoporotic effects by the single compound and to compare their representive effects.

*Pueraria montana* (Lour.) Merr {#s2_12}
-------------------------------

The Chinese herb of *Pueraria montana* (Lour.) Merr. (PM, "Ge Gen") has been famously used for the daily diet and medicine in China and other Asia countries from ancient years. Being a classical and antioxidant agent, it had more recently exhibited benefits for the treatment of angina pectoris and hypertension ([@B188]; [@B144]), neurological health ([@B35]), blood glucose homeostasis ([@B127]), and bone metabolism ([@B106]).

Puerarin is an active and famous isoﬂavone compound extracted from the classical Chinese medicine *P. montana*. Puerarin treatment with intragastric administration protected against the decreased levels of BMD and BMC, and the poor structure of femur trabecular bone in ovariectomized rats was improved ([@B156]). In the *in vivo* study with orchidectomized (ORX) osteoporotic model, the BMD of the femur was significantly decreased. PM treatment of diet intake effectively decreased the impaired BMD, and the analysis of the femoral metaphysis indicated that PM significantly decreased the levels of BV/TV and trabecular number. And the enhancement of trabecular separation in ORX mice was restored ([@B158]; [@B192]). In the experiment with natural menopausal monkeys, the treatment of 1000 mg/kg body weight of Puerarin powder for 16 months could significantly alleviate the loss of cortical bone. And the bone turnover levels of serum ALP and osteocalcin were decreased ([@B62]). Puerarin 6''-O-xyloside (PXY), one of the major isoflavones of the *P. montana* had the beneficial effects to improve the levels of calcium, phosphorus, ALP activity, and OPG which had been decreased after OVX surgery in ICR mice serum. The destructive femur osseous tissues of enlarged bone marrow cavity and sparse trabecular bone were alleviated with PXY treatment. Correspondingly, PXY effectively improved the proliferation of osteoblasts *via* the improvement in the expression of OPG/RANKL ratio ([@B69]).

In the *vitro* study, Puerarin could stimulate and improve the proliferation and differentiation of osteoblast cells ([@B161]; [@B162]). The stimulation of osteoprotegerin and inhibition of RANKL and interleukin-6 production may act *via* the classic estrogen response element (ERE) pathway in MG-63 cells ([@B162]). And the expression of OPG mRNA was increased by Puerarin in MC3T3-E1 osteoblast cells ([@B192]). Puerarin at the dose of 2.5-100 µM would increase the growth of human BMSCs concentration-dependently ([@B102]). The osteoblastic maturation would be stimulated with the increased ALP activity, as well as the formation of mineralized nodules by Puerarin ([@B156]; [@B102]; [@B194]). The signalling pathways of classical ER, MAPK, and Wnt/β-catenin were involved in the osteogenesis and bone formation effects stimulated by Puerarin treatment ([@B156]). Lv et al. found that the osteogenesis marker expressions of Runx2, osterix, and osteocalcin were enhanced *via* the increased nitric oxide production and cyclic guanosine monophosphate content in hBMSCs ([@B102]). And Zeng et al. reported that the expression of transient receptor potential Melastatin 3 (TRPM3) and miR‐204 were decreased and the activation of Runx2 was promoted following puerarin treatment in MC3T3‐E1 osteoblastic cells ([@B194]). Additionally, Puerarin opposed the apoptosis of human osteoblast cells induced by cisplatin or in the serum-free condition. The expression of Bcl-xL and Bcl-2 was up-regulated and Bax was decreased *via* the activation of MEK/ERK and PI3K/Akt signalling ([@B88]; [@B161]).

PM could also inhibit the formation of osteoclasts *in vitro*. *Pueraria montana* extract (PME) could dose-dependently inhibit osteoclast differentiation and formation from the precursor cells. Consistently, the expression of osteoclast differentiation markers including *c-Fos* and *NFATc1* genes were downregulated ([@B124]). MAPK activity induced by RANKL had also been effectively inhibited by PME treatment ([@B124]). In the *vitro* experiment with RAW 264.7 cells, PM reduced the formation of TRAP-positive cells induced by the stimulation of RANKL. Correspondingly, the mRNA expression of RANKL was inhibited ([@B192]).

These results strongly suggest that *P. montana* could act as both effective promotors of osteogenesis and inhibitor of RANKL-induced osteoclastogenesis, and it appears the isoﬂavon compounds of Puerarin and PXY have the great promotion on osteogenesis ability in the *in vivo* and *in vitro* studies. Even Pueraria Montana may be a potential therapeutic agent for the treatment of bone loss diseases, while the definite extracts of PM to inhibit osteoclastogenesis were still not well known and studied. Further research is necessary to characterize the bioactive compounds of CM which contains anticatabolic or anabolic benefits for the treatment of osteoporosis, and their molecular mechanisms providing the antiosteoporotic effects.

*Salvia miltiorrhiza* Bunge {#s2_13}
---------------------------

*Salvia miltiorrhiza*Bunge (SMB, "Dan Shen") has been widely and classically used in clinical practice and trial for the treatment and prevention of vascular diseases in liver and heart, as well as commonly used for treating trauma wounds and fractures and correcting blood stasis in TCM for its antioxidant properties ([@B9]; [@B205]; [@B13]). The application of Salvianolate, Salvianolic acid B on the treatment of osteoporosis has been deeply studied ([@B38]).

Salvianolate could control the metabolism of bones in glucocorticoid-treated lupus-prone mice. Lupus mice usually have a marked bone loss and deterioration due to an imbalance of bone formation and resorption. Glucocorticoid treatment would deeply restrain their bone formation. After the treatment, Salvianolate increased the trabecular qualities of BV/TV, Conn.D, and Tb.Th, and decreased the SMI number in both the untreated and GC-treated lupus mice. The mechanical parameters of bone ultimate load, yield load, and stiffness in treated lupus mice were significantly improved ([@B94]). Correspondingtly, the bone resorption maker of serum TRAcP was down-regulated and OPG level was increased. The expression of RANKL, IL-6, ROS, and PPARγ was inhibited, while the Runx2 expression was increased in the mice. These results indicated that Salvianolate treatment significantly affected bone metabolism to inhibit bone loss in lupus mice ([@B94]). The compound of Salvianolic acid B could prevent glucocorticoid-induced decreased BMD, bone strength, and serious architecture, and could effectively enhance the bone formation rate and the local microcirculation with more capillary dilation ([@B18]).

There are many compounds in *S. miltiorrhiza* having the pro-osteogenesis abilities including water solution, Salvianic acid A, Salvianolic acid B, Tanshinol, and Tanshinone IIA. The water solution of *Salvia miltiorrhiza* improved bone remodelling by enhancing the gene expression of *ALP*, *OCN*, and *OPG* ([@B15]). Salvianic acid A protected bone metabolism from serious impairment by the stimulation on osteogenesis and the depression of adipogenesis induced by prednisone ([@B19]). It was reported that Salvianolic acid B had the potential to stimulate the ALP activity of osteoblastic cells ([@B96]). It could also protect BMSCs differentiation and increase osteoblast activities *via* the increase of Runx2 mRNA expression even with the exposure of glucocorticoid. The glucocorticoid associated adipogenic differentiation was decreased by the regulation of PPARγ mRNA expression ([@B18]). In the *vivo* study with rat tibia fracture model, Salvianolic acid B could accelerate the early-stage fracture healing for that the callus growth in the fractured bone was significantly greater in the Salvianolic acid B treated group. And the serum ALP level of the fracture rats was enhanced at weeks 1 and 3 postfracture. These findings indicate that Salvianolic acid B is a potential candidate to treat bone fracture and osteoporosis by the promoting effects on bone formation ([@B41]). In another experiment with zebrafish *in vivo*, dexamethasone exposure had a series of serious impairment to the bone formation, bone mass, and osteoblast-specific genes. While Tanshinol protectively promoted bone formation and bone mass *via* the inhibition of oxidative stress, and the osteoblast-specific genes expression of *Runx2*, *osteocalcin*, *ALP*, and *osterix* were stimulated ([@B100]). Additionally, Tanshinone IIA blocked the apoptosis of osteoblasts induced by glucocorticoids *via* the inhibition on the Nox4-derived overexpressed reactive oxygen species activities ([@B70]). And Tanshinone IIA enhanced the differentiation of C2C12 cells to osteoblasts *via* activating the signalling pathways of p38, BMP2/Smad, and Runx2 ([@B58]). It could also enhance the osteogenic differentiation of human periodontal ligament stem cells *via* enhancing the activation of both ERK and Runx2 ([@B93]).

In the *in vivo* study, after SMB treatment at the concentration of 5 g/kg for 14 weeks, the unbalanced levels of serum ALP, OPG, TRAcP, and RANKL of OVX rats were attenuated. The decreased BMD and bone strength was inhibited, and the impaired bone microstructures were improved. Moreover, the decreased expression of p‐LRP6, IGF‐1, ALP, and OPG were enhanced. While the increased expression of RANKL and CTSK in the tibias and femurs of OVX rats were effectively inhibited by SMB treatment ([@B87]). Tanshinone VI, extracted from the root of *S. miltiorrhiza*, which could greatly inhibit osteoclast differentiation and bone resorption by disrupting the formation of actin ring. Tanshinone VI appears to prevent osteoclast differentiation by the downregulation of RANKL expression ([@B115]). Kwak et al. reported that Tanshinone IIA inhibited the osteoclast differentiation from the precursors *via* the down-regulation of RANKL-induced high levels of c-Fos and NFATc1 ([@B63]). Additionally, in the natural drug screening experiment, maybe tanshinone 1, cryptotanshinone, and 15,16-dihydrotanshinone I diterpenoids and other unknown compounds had a synergistic effect with tanshinone, possessing the antiosteoclastogenesis effects by reducing the formation and function of TRAP-positive multinuclear osteoclasts ([@B65]; [@B60]).

These studies highlight the antiosteoporotic effects of *S. miltiorrhiza in vivo* and *in vitro*. Most of the compounds of *S. miltiorrhiza* including Salvianolate, Salvianic acid A, Salvianolic acid B, Tanshinol, and Tanshinone IIA, and so on, have potential antiosteoporosis effects by promoting bone formation *via* increased expression of osteogenesis-related genes and proteins, and by decreasing bone resorptive osteoclastogenesis through the inhibition of reactive oxygen species activity. Compounds in the research of Kim et al. also have the antiosteoclastogenic effects which are not further studied. More research is needed to provide the evidence of the herb and its potent compounds to target osteoporosis in clinical trials, including their mode of application and mechanisms of action.

Discussion {#s3}
==========

In summary, with the increasingly ageing population worldwide, the osteoporotic fracture has become a major health and social issue. The side effects caused by hormone therapy and alendronate antiosteoporotic agents have prompted researchers to study natural therapeutic compounds, which may be effective and safe for the treatment of osteoporosis, and with less adverse side-effects.

The pathophysiology of osteoporosis is complicated in terms of occurrence, development, and progression, including much more numerous mechanisms of mechanistic/mammalian target of rapamycin (mTOR), autophagy, and notch involved ([@B133]; [@B193]; [@B44]), except for RANKL, MAPK, Wnt, and Smad signalling pathways discussed above. Natural Chinese medicine may contain compounds that are effective for the treatment of osteoporosis and this review documents current evidence as to their potential bio-pharmacological effects and possible mechanisms of actions. A summary of the *in vivo* and *in vitro* antiosteoporosis effects of the natural herbs reviewed by this article is presented in [**Table 1**](#T1){ref-type="table"} and [**Table 2**](#T2){ref-type="table"}, respectively. Natural Chinese medicine appears to promote bone formation activity, including the osteogenesis of MSCs and osteoblasts. Some medicines could protect them from oxidative damage due to ROS activity. Additionally, the bone resorption activity of osteoclasts may be significantly inhibited by certain herbal compounds, thus potentially alleviating the imbalance between bone formation by osteoblasts and bone resorption by osteoclasts. [**Figure 3**](#f3){ref-type="fig"} summarizes the signalling pathways that appear to mediate the antiosteoporotic effects of the natural medicine reviewed by this article.

###### 

Summary of *in vivo* studies for the antiosteoporotic effects of natural Chinese medicine.

  TCM                                                                                             Compound                           Animal model                                                                     Beneficial effects
  ----------------------------------------------------------------------------------------------- ---------------------------------- -------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------
  *Gynochthodes officinalis* (F.C.How) Razafim. & B.Bremer (syn. *Morinda officinalis* F.C.How)   MO extract                         OVX rats                                                                         BMC, BMD, serum P, Ca2+ and OPG↑ AKP and TRAP ↓([@B71]; [@B77])
                                                                                                  Disuse OP rats                     tibia BMD, histomorphometrical parameters↑ osteoblasts↑ osteoclast ↓ ([@B131])   
  polysaccharides Monotropein                                                                     OVX rats                           BMC, BMD, mineral element levels↑ ([@B212]; [@B207])                             
  *Curculigo orchioides*                                                                          CO extract                         OVX rats                                                                         BMC, BMD, and serum OPG↑ serum DPD/Cr, TRAcP ↓([@B4])
                                                                                                                                     rabbits                                                                          bone defects↓ ([@B172])
  *Psoralea corylifolia*                                                                          PC extract                         OVX rats                                                                         BMD, ash weight and calcium content↑ ([@B148])
                                                                                                                                     rachitic rats                                                                    serum phosphorus, bone calcification and hyperosteoidosis ↑ ([@B110])
                                                                                                  Bavachin, bakuchiol                OVX rats                                                                         BMD, trabecular parameters↑ ([@B84]; [@B170])
                                                                                                  Psoralen                                                                                                            BV, Tb. Th, osteocalcin ↑ ([@B189])
  *Eucommia ulmoides*                                                                             EU cortex extract                  OVX rats                                                                         BMD, biomechanical parameters and microarchitecture↑ ([@B201]; [@B122]; [@B202])
                                                                                                                                     disused OP rats                                                                  
                                                                                                  TL                                 OVX rats                                                                         
                                                                                                  EU leaf extract                    OVX rats                                                                         BMD, biomechanical parameters, serum OC↑ ([@B203])
                                                                                                  EU seed extract                    healthy rats                                                                     BMD, microarchitecture↑ ([@B78])
  *Dipsacus inermis*                                                                              RD extract                         healthy rats                                                                     bone density, bone histomorphology↑ ([@B173])
                                                                                                  RDE RTS                            OVX rats                                                                         BMD, BMC, microstructure, Young's modulus, serum OC and ALP↑ ([@B97]; [@B120]; [@B91]; [@B117])
                                                                                                                                     Disuse OP rats                                                                   
  *Cibotium barometz*                                                                             CB extract                         OVX rats                                                                         BMD, bone strength, bone metaphysis↑ ([@B210])
  Velvet Antler                                                                                   blood                              OVX rats                                                                         BMD, IGF-1, testosterone↑ ([@B185])
                                                                                                  VA and blood combination           OVX rats                                                                         Microarchitecture, strength, serum ALP↑ ([@B150])
                                                                                                  TVAPL                              OVX rats                                                                         BWC, BMC, BMD, microarchitecture↑ ([@B199])
  *Cistanche deserticola*                                                                         CD extract                         OVX rats                                                                         BMD, BMC, biomechanical parameters↑ ([@B81]) E~2~, Smad1, Smad5, TGF-β1 and TIEG1↑ ([@B82])
                                                                                                  Echinacoside                       OVX rats                                                                         BMD, microarchitecture and biomechanical parameters↑ ([@B67])
  *Cuscuta chinensis*                                                                             Kaempferol                         OVX rats                                                                         BMD, Young's modulus↑([@B121])
  *Cnidium monnieri*                                                                              osthole                            bone fracture                                                                    bone growth, maximum load↑ ([@B208])
                                                                                                                                     OVX rats                                                                         maximal load↑ ([@B75])
                                                                                                                                     heathy rats                                                                      peak bone mass, serum OC, micro-architecture, biomechanical parameters↑ ([@B14])
  *Epimedium brevicornum*                                                                         Icariin flavonoids                 OVX rats C57BL/6 mice and GIOP                                                   BMD, serum ALP, OC, micro-architecture, biomechanical parameters↑([@B196]; [@B126]; [@B83]) Serum TRACP 5b, CTX↓([@B31]; [@B198])
  Pueraria montana                                                                                Puerarin Puerarin 6''-O-xyloside   ORX and OVX rats, monkeys                                                        BMD and BMC, serum ALP, OCN↑ ([@B158]; [@B62]; [@B192])
  *Salvia miltiorrhiza*                                                                           Salvianolate Salvianolic acid B    Lupus mice GIOP                                                                  bone mechanical parameters, RUNX2 expression↑ Serum TRACP, RANKL, IL-6, ROS↓([@B18]; [@B94])

They could enhance the BMC, BMD, and biomechanical parameters of the bones in osteoporosis model animals. And some of the osteogenesis makers of phosphorus, Ca^2+^, osteocalcin, osteoprotegerin, and ALP in serum would be alleviated during the dynamic metabolism progress of bone formation and resorption.

###### 

Summary of *in vitro* studies for the antiosteoporotic effects of natural Chinese medicine.

  TCM                                                                                             Compound                                                           Cells                                                           Beneficial effects
  ----------------------------------------------------------------------------------------------- ------------------------------------------------------------------ --------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------
  *Gynochthodes officinalis* (F.C.How) Razafim. & B.Bremer (syn. *Morinda officinalis* F.C.How)   Bajijiasu                                                          OCs                                                             osteoclast formation↓ ([@B45])
  anthraquinone                                                                                   OBs                                                                proliferation↑ ([@B177])                                        
                                                                                                  OCs                                                                differentiation, TRAcP activity↓, apoptosis↑ ([@B177]; [@B2])   
  Monotropein                                                                                     OBs                                                                Proliferation, mineralization↑ ([@B207])                        
  *Curculigo orchioides*                                                                          Curculigoside (CCG)                                                hAFSCs                                                          osteogenesis, ALP activity, calcium deposition↑ osteoclastogenesis↓ ([@B89])
                                                                                                                                                                     BMSCs                                                           Proliferation, differentiation↑ ([@B134])
                                                                                                                                                                     OBs                                                             oxidative damage↓, proliferation, differentiation↑ ([@B163])
                                                                                                  M2, CCG-A, CCG-B etc.                                              OBs                                                             proliferation, differentiation↑ ([@B153])
                                                                                                                                                                     OCs                                                             TRAcP activity↓ ([@B54]; [@B166]; [@B159])
  *Psoralea corylifolia*                                                                          bavachin and bakuchiol                                             OBs                                                             Proliferation, differentiation, ALP activity↑ ([@B84])
                                                                                                  PSO                                                                MSCs                                                            differentiation, ALP activity↑ ([@B189])
                                                                                                  Neobavaisoflavone                                                  OBs                                                             differentiation, ALP activity↑ ([@B24])
                                                                                                  bavachalcone                                                       OCs                                                             osteoclastogenesis, resorption pits↓ ([@B6])
  *Eucommia ulmoides*                                                                             5-HMF                                                              MSCs                                                            osteogenesis Mineralization↑ ([@B146])
                                                                                                                                                                                                                                     adipogenesis↓ ([@B146])
                                                                                                  AU, GP, GA, TL                                                     OBs                                                             proliferation↑ ([@B39]; [@B202])
                                                                                                                                                                     OCs                                                             proliferation, differentiation↓([@B39]; [@B202])
  *Dipsacus inermis*                                                                              RDE, RTS                                                           OBs, MSCs                                                       proliferation, differentiation↑ ([@B91]; [@B118])
                                                                                                                                                                     OCs                                                             osteoclastogenesis ↓ ([@B120])
                                                                                                  Asperosaponin VI                                                   OBs                                                             proliferation, differentiation, mineralization↑ ([@B119])
                                                                                                  RD extract                                                         MSCs                                                            differentiation↑ ([@B57])
  *Cibotium barometz*                                                                             RW-Cb                                                              OBs                                                             proliferation, differentiation↑ ([@B182])
                                                                                                  CB extract                                                         OCs                                                             Differentiation, TRAcP activity↓ ([@B113])
  Velvet Antler                                                                                   TVAPL                                                              OBs                                                             Proliferation, ↑ ([@B199])
                                                                                                  FA-, NFA-                                                                                                                          Proliferation, mineralization↑ ([@B64])
                                                                                                  FA                                                                 OCs                                                             Differentiation, TRAcP activity↓ ([@B16])
                                                                                                  CE-C                                                                                                                               Differentiation, actin ring↓, apoptosis↑ ([@B79])
  *Cistanche deserticola*                                                                         CD extract                                                         OBs                                                             mineralization↑ ([@B72])
                                                                                                  Echinacoside                                                       OBs                                                             proliferation, mineralization, ALP activity↑ ([@B68])
                                                                                                  CD extract                                                         OCs                                                             Differentiation, actin ring↓, ROS↓ ([@B137])
  *Cuscuta chinensis*                                                                             CC extract                                                         OBs                                                             Proliferation, differentiation mineralization↑ ([@B190]; [@B184])
                                                                                                                                                                                                                                     ALP activity, collagen synthesis, BMP-2↑ ([@B184]; [@B186])
                                                                                                                                                                                                                                     oxidative damage↑, apoptosis↓ ([@B34])
                                                                                                  Kaempferol, hyperoside                                             OBs                                                             ALP activity↑ ([@B186])
                                                                                                  Campesterol                                                        OCs                                                             osteoclasts activities↓ ([@B190])
  *Cnidium monnieri*                                                                              Osthole                                                            OBs                                                             Proliferation, ALP, mineralization↑([@B51]; [@B208])
                                                                                                  Bergapten                                                          OCs                                                             Osteoclastogenesis and bone resorption↓ ([@B10])
  *Epimedium brevicornum*                                                                         Icariin, etc.                                                      OBs and MSCs                                                    Proliferation, ALP, mineralization, COL1a2, OSX, RUNX-2, BMP-2/Smad4 Notch2↑([@B12]; [@B111]; [@B29]; [@B5]; [@B83])
                                                                                                                                                                     OCs                                                             Osteoclastogenesis, bone resorption, RANKL, CTSK, TRAcP and MMP9↓([@B11])
  *Pueraria montana*                                                                              Puerarin                                                           OBs, MSCs                                                       proliferation and differentiation, ALP activity↑ ([@B161]; [@B162])
                                                                                                                                                                     OCs                                                             osteoclast differentiation and formation↓([@B124])
  *Salvia miltiorrhiza*                                                                           Salvianic acid A Salvianolic acid B Tanshinol and Tanshinone IIA   OBs,                                                            ALP, OCN, OPG, Runx2↑([@B15]; [@B19])
                                                                                                                                                                     OCs                                                             Osteoclast formation and function, c-Fos and NFATc1↓([@B115]; [@B87])

They have beneficial osteogenetic effects by enhancing the proliferation and differentiation of osteoblasts and bone mesenchymal stem cells, improving the activity of ALP and the formation of mineralized nodules. While the osteoclastogenesis and function of osteoclasts are inhibited.

![Signalling pathways involved in the anabolic and anticatabolic effects of natural Chinese medicine to treat osteoporosis, including classical Wnt/β-catenin, TGF-β/Smad, BMP2, Notch, RANKL, MAPK, and NFATc1 families.](fphar-10-01344-g003){#f3}

The natural Chinese medicines in this review are classic and bone-specific medicines. As we know, clinical experiences are very important to Chinese medicine. Chinese medicines were classified into different categories with special functions according to the rich practices and experiences in the clinic and the Chinese medicine theories. Some of them were the classic and bone-specific drugs to treat skeleton fractures and bone loss diseases for their beneficial improvement on bone formation. Most of them have the effects and functions to tonify the "Yang" in traditional Chinese medicine, which has an improvement on bone development and metabolism. "Yang-tonifying" medicines are the most popular and classic kind of natural drugs to treat osteoporosis in Chinese medicine ([@B56]; [@B76]). Furthermore, all of them are deeply studied possessing both anabolic and anticatabolic effects. They have potential bone-formation effects by enhancing the proliferation and differentiation of osteoblasts and BMSCs, improving the activity of ALP and mineralization formation. Some of them could protect osteoblasts and BMSCs from apoptosis induced by oxidative stress ([@B88]). While the osteoclastogenesis and bone-resorption function of osteoclasts were inhibited by the treatment of these medicines ([@B162]). Interestingly, they have the phytoestrogenic or phytoandrogenic effects which might act as the natural and potential alternatives for hormone replacement treatment or alendronate therapies to significantly inhibit the bone loss and improve skeleton development of osteporotic patients. It has been reported that testosterone played a vital basic and clinical role in the homeostasis of skeletal tissue ([@B26]). In vivo study indicated that the androgen deficiency would significantly lead to an increase of osteopenia in the aged male rats ([@B28]). Clinically, testicular malfunction induced by androgen deficiency may cause the osteoporosis in old men with increasing bone resorption ([@B32]). Numerous studies indicated that these bone-specific drugs contain phytoandrogens ([@B27]), which could act as a natural and potential alternative for testosterone replacement therapy (TRT). They could effectively restore the level of serum testosterone and thus significantly improve the bone health and physical condition of patients ([@B36]). Some studies found that the compounds from these classical drugs may also possess phytoestrogenic effects ([@B54]; [@B103]; [@B206]), having a similar structure of estrogen conformation and capabilities to bind with estrogen receptors. Therefore, they may regulate bone remodeling *via* estrogen receptor pathway ([@B171]). More importantly, the application of these drugs exhibiting phytoandrogen and phytoestrogen effects do not appear to cause obvious or harmful side-effects including cardiovascular disease, prostate cancer, and breast cancer, which might be induced by the long-term and large dosage use of testosterone or estrogen replacement therapy ([@B171]).

However, the development of osteoporosis is very complex in postmenopausal women, elderly men, glucocorticoid-overuse patients, and other patients with metabolic diseases. The mechanisms of action of natural Chinese medicines effective for the treatment of osteoporosis have not yet been well investigated, thus indicating the need for further studies ([@B56]). Besides, large dosages or long-term usage warrants caution and certain methodologies should be observed. Further research to isolate and characterize the bioactive antiosteoporotic compounds from the classical and bone-specific drugs is necessary to extensively profile compounds for pharmacological usage, especially their safety, efficacy, and potential chemical interactions with other drugs. Studies to determine the special and targeted cellular and molecular mechanisms of natural Chinese medicine compounds are required to develop their potential application for the treatment of osteoporosis, as an effective, safe alternative to primary therapeutic strategies, or in combination with current primary pharmacological treatments. Additionally, few high-quality clinical studies have documented the antiosteoporosis effects of structure well-known compounds, for example, Epimedium-derived phytoestrogen flavonoids were used to treat and inhibit osteoporosis and bone loss of the postmenopausal women in a clinical trial ([@B197]). There are still some limitations and deficiencies of these clinical drug findings, which are studied together with combined medicines in traditional formulas, due to the potential for unknown interactions between the various drugs and nonspecific compounds in this medicine ([@B167]; [@B169]; [@B135]). Therefore, more high-quality clinical studies with natural Chinese medicines possessing the anabolic and anticatabolic effects are needed in the future.

Conclusion {#s4}
==========

Recent *in vivo* and *in vitro* findings suggest that natural Chinese medicine may provide potential therapeutic benefits for the treatment of osteoporosis. Further research is necessary to ensure the safety, efficacy, and specificity of the compounds in Chinese medicines to develop their therapeutic potential. More high-quality clinical researches with these natural medicines are needed to provide greater evidence for the candidate to beneficial and safer antiosteoporotic application.
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